| Patrick Craig, DO | |
|
3600 E Harry St, Wichita, KS 67218-3713 | |
| (316) 689-6173 | |
| (316) 689-6192 |
| Full Name | Patrick Craig |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 11 Years |
| Location | 3600 E Harry St, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053756361 | NPI | - | NPPES |
| 201248370A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085N0700X | Radiology - Neuroradiology | DO-05177 (Iowa) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 9408058 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| Pratt Regional Medical Center | Pratt, KS | Hospital |
| Kansas Spine & Specialty Hospital, Llc | Wichita, KS | Hospital |
| Kansas Medical Center Llc | Andover, KS | Hospital |
| Via Christi Hospital Wichita St Teresa, Inc | Wichita, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas Imaging Consultants Pa | 8921082041 | 27 |
News Archive
A new report released today (25 October 2004) by the BMA paints a bleak picture of the global community's ability to cope with advances in biological and genetic weapons technology.
Further to a Letter of Intent previously reported, Genesis Bioventures today announced that it has entered into a binding agreement with Efoora Inc. and Prion Developmental Laboratories, Inc. to buy all of Efoora's majority interest shares owned or pledged in PDL thereby gaining controlling interest of PDL. A Form 8-K has been filed with the SEC in this regard. Prior to the Agreement, GBI had one-third equity interest in PDL.
Researchers report that a novel balloon catheter system, the ENABLER-P, may provide an effective method of recanalizing chronic total occlusions of the superficial femoral artery and popliteal arteries.
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.
Celiac disease (CD) is an inherited intestinal disorder characterized by life-long intolerance to the ingestion of gluten, a protein found in wheat, rye, and barley. Although CD can be diagnosed at any age, it commonly occurs during early childhood (between 9 and 24 months). Reduced bone mineral density is often found in individuals with CD.
› Verified 5 days ago
| Entity Name | Kansas Imaging Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841267663 PECOS PAC ID: 8921082041 Enrollment ID: O20040616000680 |
News Archive
A new report released today (25 October 2004) by the BMA paints a bleak picture of the global community's ability to cope with advances in biological and genetic weapons technology.
Further to a Letter of Intent previously reported, Genesis Bioventures today announced that it has entered into a binding agreement with Efoora Inc. and Prion Developmental Laboratories, Inc. to buy all of Efoora's majority interest shares owned or pledged in PDL thereby gaining controlling interest of PDL. A Form 8-K has been filed with the SEC in this regard. Prior to the Agreement, GBI had one-third equity interest in PDL.
Researchers report that a novel balloon catheter system, the ENABLER-P, may provide an effective method of recanalizing chronic total occlusions of the superficial femoral artery and popliteal arteries.
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.
Celiac disease (CD) is an inherited intestinal disorder characterized by life-long intolerance to the ingestion of gluten, a protein found in wheat, rye, and barley. Although CD can be diagnosed at any age, it commonly occurs during early childhood (between 9 and 24 months). Reduced bone mineral density is often found in individuals with CD.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick Craig, DO 200 Hawkins Dr Dept Of, Iowa City, IA 52242-1009 Ph: (319) 356-3444 | Patrick Craig, DO 3600 E Harry St, Wichita, KS 67218-3713 Ph: (316) 689-6173 |
News Archive
A new report released today (25 October 2004) by the BMA paints a bleak picture of the global community's ability to cope with advances in biological and genetic weapons technology.
Further to a Letter of Intent previously reported, Genesis Bioventures today announced that it has entered into a binding agreement with Efoora Inc. and Prion Developmental Laboratories, Inc. to buy all of Efoora's majority interest shares owned or pledged in PDL thereby gaining controlling interest of PDL. A Form 8-K has been filed with the SEC in this regard. Prior to the Agreement, GBI had one-third equity interest in PDL.
Researchers report that a novel balloon catheter system, the ENABLER-P, may provide an effective method of recanalizing chronic total occlusions of the superficial femoral artery and popliteal arteries.
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.
Celiac disease (CD) is an inherited intestinal disorder characterized by life-long intolerance to the ingestion of gluten, a protein found in wheat, rye, and barley. Although CD can be diagnosed at any age, it commonly occurs during early childhood (between 9 and 24 months). Reduced bone mineral density is often found in individuals with CD.
› Verified 5 days ago
Karl Hamouche, Radiology Medicare: Medicare Enrolled Practice Location: 551 N Hillside St Ste 320, Wichita, KS 67214 Phone: 316-685-1367 | |
Dr. Larry C Graham Ii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3600 E Harry St, Wichita, KS 67218 Phone: 316-689-5050 Fax: 316-689-6192 | |
Tim Edward Stone, Radiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
Dr. Donald C S Tan, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 817 N Emporia St, Via Christi Cancer Center, Wichita, KS 67214 Phone: 316-268-5927 | |
Elizabeth Perez-elmore, RN BSN Radiology Medicare: Not Enrolled in Medicare Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-685-2221 | |
Mike Lam, DO Radiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2635 | |
Dr. Timothy C Benning, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3600 E Harry St, Wichita, KS 67218 Phone: 316-689-6173 |